Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ardelyx: Q4 Earnings Snapshot AP - Thu Feb 19, 3:17PM CST

Ardelyx: Q4 Earnings Snapshot

ARDX : 6.74 (+0.30%)
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 19, 3:01PM CST

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs...

ARDX : 6.74 (+0.30%)
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 GlobeNewswire - Thu Feb 5, 7:00AM CST

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
Ardelyx Receives New Patent for Tenapanor GlobeNewswire - Tue Feb 3, 7:29AM CST

WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA GlobeNewswire - Wed Jan 28, 7:29AM CST

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook GlobeNewswire - Thu Jan 8, 7:30AM CST

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1   IBSRELA achieved $274 million in revenue in 2025, representing 73% growth...

ARDX : 6.74 (+0.30%)
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week GlobeNewswire - Fri Nov 7, 2025

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London GlobeNewswire - Wed Nov 5, 2025

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference GlobeNewswire - Tue Nov 4, 2025

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.74 (+0.30%)
Ardelyx: Q3 Earnings Snapshot AP - Thu Oct 30, 2025

Ardelyx: Q3 Earnings Snapshot

ARDX : 6.74 (+0.30%)

Barchart Exclusives

Kraft Heinz Pauses Its Breakup Plans. Should You Buy the High-Yield Dividend Stock Here? Barchart - 14 minutes ago
Kraft Heinz is still facing many tough challenges. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot